Trials / Completed
CompletedNCT00044031
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 394 (actual)
- Sponsor
- Cancer Advances Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | G17DT Immunogen |
Timeline
- Start date
- 2001-02-01
- Primary completion
- 2004-04-01
- Completion
- 2007-10-01
- First posted
- 2002-08-20
- Last updated
- 2014-04-17
Source: ClinicalTrials.gov record NCT00044031. Inclusion in this directory is not an endorsement.